Efficacy of Somatostatin Analogs (SSA) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) According to Ki67 Index: A Single Centre Experience

R. Marconcini1, S. Ricci2, E. Vasile1, L. Gali1, A. Antonuzzo2, L. Derosa1, A. Farnesi1, E. Biasco1, E. Bracco1, R. Vaglialoro1, A. Sbrana1, A. Falcone1
1U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria S. Chiara, Pisa, ITALY
2Oncologia, Trapianti E Nuove Tecnologie In Medicina, Polo Oncologico - Azienda Ospedaliero-Universitaria Pisana - Istituto Toscano Tumori, Pisa, ITALY

Aim: PROMID and CLARINET studies showed antitumor activity associated with SSA, respectively Octreotide LAR (Oc) and Lanreotide LAR (La) in low grade GEP-NET. PROMID enrolled Ki67 index <2% patients (pts), CLARINET enrolled Ki67 index <10% pts. In this study we analyze our experience with Oc and La in metastatic GEP-NET, including those with Ki67 index >10%.

Methods: A retrospective analysis was conducted on 137 patients (pts) with advanced GEP-NET treated upfront with Oc (30 mg 1 fl every 28 days) or La (120 mg 1 fl every 28 days) until disease progression. 87 gastrointestinal (GI) NET pts, 50 pancreatic (P) NET pts. Ki67 was specified in 89 pts and it was <3% in 38 pts, 3-5% in 15 pts, 5-10% in 15 pts, >10% in 21 pts. Toxicity was evaluated based on CTCAE v4.0, response according RECIST Criteria.

Results: Median time from NET diagnosis and SSA treatment was 5.2 months (0.5 - 1121 months). Partial response was obtained in 12 pts (9%), stable disease in 112 pts (81%), and progressive disease in 13 pts (10%). In pts treated with Oc and La, median PFS was respectively 24.6 and 21.83 months. In GI NET pts and P NET pts, median PFS was respectively 21.73 and 24.73 months. In pts with Ki67 index <2%, 2-5%, 5-10%, >10%, median PFS was respectively 27.15, 34.77, 28.3, 20 months.

Conclusions: Oc and La showed comparable efficacy in terms of PFS in both PNET and GI NET, in all Ki67 index groups, suggesting that SSA treatment is efficacious also in Ki67 >10% pts.

Disclosure: All authors have declared no conflicts of interest.